This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 38/4/1396    most recent 01.STR.0000260101.08944.e9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hachinski, V. Search for Related Content PubMed PubMed Citation Articles by Hachinski, V. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Other Stroke Treatment - Medical

(Stroke. 2007;38:1396.)
© 2007 American Heart Association, Inc.

Special Report

Stroke and Vascular Cognitive Impairment

A Transdisciplinary, Translational and Transactional Approach

From the University of Western Ontario, London, Canada.

Correspondence to Vladimir Hachinski, MD, FRCPC, DSc, Stroke Editorial Office, 100 Collip Circle, Suite 116, London, Ontario, Canada, N6G 4X8. E-mail stroke{at}lhsc.on.ca

Advances in stroke are occurring at an unprecedented pace, but often in disciplinary isolation and without optimal mechanisms for systematically translating, integrating and applying the findings.

Knowledge accrues in pieces, but is understood in patterns. To optimize knowledge acquisition and application, infrastructures and systems need to be set up along with appealing incentives. The approach needs to be transdisciplinary, going beyond the bounds of any given discipline, reciprocally translational, and transactional, meaning that the interchanges have to yield previously agreed benefits to the parties (The Triple T Approach). A new breed of leaders needs to be developed and nurtured to catalyze the process.

Opportunities abound. Stroke and most brain diseases share the same pathophysiological fundamental mechanisms. An integrated, systematic approach to these processes could yield not only greater understanding but new, common therapeutic targets for several diseases. Biphasic clinical trials could combine the best features of pragmatic and explanatory, randomized clinical trials. The greatest opportunity of all may be the largely under-explored and under-exploited borderlands between cerebrovascular and Alzheimer disease. One in three of us will have a stroke, become demented, or both. For each person who has a stroke or Alzheimer disease, two have some cognitive impairment short of dementia, often subclinical cerebrovascular disease on a substrate of Alzheimer changes. The fact that cerebrovascular and Alzheimer disease share the same risk factors, provide a great opportunity for prevention, if implemented at the "brain at risk" stage.

Systematically integrating what we know and evaluating what we do could spur progress. Research is not only an activity but an attitude. Making evaluation and incentives to excel part of the funding of all stroke activities would yield far ranging cumulative improvements in all aspects of stroke.

No system can replace the individual initiative, creativity and insights that lead to the great discoveries, but progress is not made by breakthroughs alone. No one’s work is so exalted that it cannot be improved, nor so humble that it has no value. We can all make a difference.

Key Words: Alzheimer disease • clinical trials • discovery • intervention • stroke • treatment • vascular cognitive impairment

This article has been cited by other articles:

				R. H. Swartz, D. T. Stuss, F. Gao, and S. E. Black Independent Cognitive Effects of Atrophy and Diffuse Subcortical and Thalamico-Cortical Cerebrovascular Disease in Dementia Stroke, March 1, 2008; 39(3): 822 - 830. [Abstract] [Full Text] [PDF]

				P. B. Gorelick and J. V. Bowler Advances in Vascular Cognitive Impairment 2007 Stroke, February 1, 2008; 39(2): 279 - 282. [Full Text] [PDF]

				H. Aleyasin, M. W. C. Rousseaux, M. Phillips, R. H. Kim, R. J. Bland, S. Callaghan, R. S. Slack, M. J. During, T. W. Mak, and D. S. Park The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage PNAS, November 20, 2007; 104(47): 18748 - 18753. [Abstract] [Full Text] [PDF]

				R. L. Sacco The 2006 William Feinberg Lecture: Shifting the Paradigm From Stroke to Global Vascular Risk Estimation Stroke, June 1, 2007; 38(6): 1980 - 1987. [Abstract] [Full Text] [PDF]